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Abstract 
Background: MicroRNAs (miRNAs) are short non-protein-coding RNA species that have a regulatory function in 
modulating protein translation and degradation of specific mRNAs. MicroRNAs are estimated to target approximately 
60 % of all human mRNAs and are associated with the regulation of all physiological processes. Similar to many mes-
senger RNAs (mRNA), miRNAs exhibit marked tissue specificity, and appear to be dysregulated in response to specific 
pathological conditions. Perhaps, one of the most significant findings is that miRNAs are detectable in various biologi-
cal fluids and are stable during routine clinical processing, paving the way for their use as novel biomarkers. Despite 
an increasing number of publications reporting individual miRNAs or miRNA signatures to be diagnostic of disease or 
indicative of response to therapy, there is still a paucity of baseline data necessary for their validation. To this end, we 
utilised state of the art sequencing technologies to determine the global expression of all circulating miRNAs within 
the plasma of 18 disease-free human subjects.
Results: In excess of 500 miRNAs were detected in our study population with expression levels across several orders 
of magnitude. Ten highly expressed miRNAs accounted for 90 % of the total reads that mapped showing that despite 
the range of miRNAs present, the total miRNA load of the plasma was predominated by just these few species (50 % 
of which are blood cell associated). Ranges of expression were determined for all miRNA detected (>500) and a set of 
highly stable miRNAs identified. Finally, the effects of gender, smoking status and body mass index on miRNA expres-
sion were determined.
Conclusions: The data contained within will be of particular use to researchers performing miRNA-based biomarker 
screening in plasma and allow shortlisting of candidates a priori to expedite discovery or reduce costs as required.
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Background
MicroRNAs (miRNAs) are short non-protein-coding 
RNA species that have a regulatory function in modulat-
ing protein translation from specific mRNAs [3]. Micro-
RNAs are estimated to target approximately 60  % of all 
human mRNAs [7] and are associated with the regulation 
of all physiological processes. Similar to many messenger 
RNAs (mRNA), miRNAs exhibit marked tissue specific-
ity [9, 12], and appear to be dysregulated in response to 
specific pathological conditions [3]. Perhaps most signif-
icant is the finding that miRNAs are detectable in vari-
ous biological fluids [19] and are stable during routine 
clinical processing [13], paving the way for their use as 
novel biomarkers. Whilst the presence of extra-cellular 
miRNAs in a range of biological fluids has been consist-
ently described within the recent literature, the precise 
mechanisms via which they leave their “host cell” and 
enter the circulation are still under investigation. Never-
theless, it is now accepted that miRNAs are not simply 
shed from necrotic or apoptotic cells but rather, are sub-
ject to selective export from specific cells and function as 
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extra-cellular signalling molecules, retaining their biolog-
ical activity in recipient cells [1].
In considering the use of miRNAs as novel biomark-
ers, it is essential to generate baseline data that describes 
which miRNA species are present in a given biological 
fluid, where they likely originate from, and what is con-
sidered normal in terms of their patterns of expression. 
Indeed, we take such data for granted when we consider 
other routine clinical analyses such as the measurement 
of plasma/serum aspartate aminotransferase and alanine 
aminotransferase for the determination of liver func-
tion. Despite an increasing number of publications (5897 
articles indexed by PubMed at the time of publication) 
reporting individual miRNAs or miRNA signatures as 
biomarkers of various conditions, there is still a paucity of 
baseline data necessary for their validation. To date, there 
are no comprehensive assessments of plasma miRNA 
expression conducted using unbiased methodology (i.e. 
where the miRNA targets are not required a priori) in a 
representative set of healthy human subjects reported. To 
this end, we utilised state of the art sequencing and bioin-
formatic techniques to determine the global expression of 
all circulating miRNAs within the plasma of 18 disease-
free human subjects with high resolution. We report data 
to support the key questions outlined above including (1) 
a comprehensive list of all miRNAs found within human 
plasma, (2) the expected range of expression in a disease-
free cohort and (3) the likely tissue of origin for a selec-
tion of the most highly expressed miRNAs. Furthermore, 
we report the effects of sex, smoking status and differing 
body mass index (BMI) on these parameters.
Results and discussion
All data presented herein are derived from 18 human 
plasma specimens, details of which can be found in 
Table  1. Circulating RNA was extracted from 5  mL of 
each plasma sample, yielding an average RNA mass of 
0.01  µg (Table  2). The mass of RNA obtained was con-
sistent irrespective of gender (P > 0.05; two-tailed t test; 
n = 9). Next generation sequencing for small RNA mole-
cules yielded an average of 8,080,000 high quality (≥Q30) 
sequencing reads per sample (Fig.  1). Raw sequencing 
data in fastq format can be obtained from the Short Read 
Archive (SRA), accession number SRP064104. Map-
ping of the raw sequencing data to miRBase version 20.0 
(Fig.  2a) identified 548 different miRNAs across the 18 
samples analysed. Of these, only 53 were present in all 
samples (Table 3). The number of reads mapped and the 
number of miRNAs identified in each plasma sample is 
detailed in Fig. 2b, c respectively.
Normalised miRNA expression values were used to 
compare the expression of individual miRNAs between 
plasma samples (Additional file  1: S1). In the first 
instance, we investigated which miRNAs were most 
abundantly expressed in human plasma. Based upon the 
mean expression of 18 independent samples, microR-
NAs 486-5p, 10b-5p, 320a, 423-5p, 92a-3p, 22-3p, 10a-
5p, 181a-5p, 151a-3p, and let-7f-5p were found to be 
Table 1 Details of the donor population
Age—rounded to the nearest whole year, Smoking status—self reported, BMI body mass index (patients with a BMI > 30 were considered obese)
Sample number Sample name Sex Age (range) Smoking BMI (range) Obese
1 FA01 F 40 (20–61) (4/9) 35 (24–46) (7/9)
2 FA02
3 FA03
4 FA04
5 FA05
6 FA06
7 FA07
8 FA08
9 FA09
10 MA01 M 39 (19–67) (4/9) 28 (18–47) (2/9)
11 MA02
12 MA03
13 MA04
14 MA05
15 MA06
16 MA07
17 MA08
18 MA09
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most abundantly expressed in the plasma of our study 
participants. Surprisingly, the most abundant miRNA 
(miR-486-5p) accounted for almost 60  % of the total 
number of sequencing reads mapping to miRNAs and 
furthermore, the ten most abundant miRNAs accounted 
for approximately 90 % of mapped reads. To verify these 
striking findings, we reviewed the results of thirty-seven 
publically available plasma miRNA-seq datasets obtained 
via miRmine online (Guan Laboratory, University of 
Michigan—Additional file 1: S1, sheet 2) and undertook 
a complete re-analysis (from raw sequencing data) of 
three randomly selected plasma sequencing runs from 
the short read archive [accession numbers; SRR1005875, 
SRR1005877 and SRR1005876]. The top ten miRNAs 
accounted for 68 and 74  % of the total mapped read 
count in the reviewed and re-analysed datasets respec-
tively. The fraction of the total plasma miRNA read count 
attributed to each of the top 10 most highly expressed 
miRNAs is detailed in Fig.  3 (left-hand axis). The nor-
malised expression (reads per million; RPM expressed 
in Log 2 scale) of each of these miRNAs in human whole 
blood, serum and plasma (using publically available data 
via miRmine) is included on the right-hand axis. Com-
parison of plasma data from this study and those derived 
from miRMine revealed no clear correlation, however, 
significant variation within the later dataset may explain 
this finding (Fig. 3, right-hand axis error bars).
Next we sought to determine the origin of these highly 
expressed miRNAs. As per the available literature, five 
out of the ten most highly expressed miRNAs were pre-
viously identified as being highly expressed by cells of 
the blood. MicroRNAs 486-5p and 92a-3p were shown 
Table 2 Total RNA concentration derived from  5  mL 
of human plasma
Samples prefixed with FA are from female donors, those prefixed with MA are 
from male donors. RNA concentrations determined using the QuBit fluorimeter, 
invitrogen
Sample number Sample name Total mass RNA (µg)
1 FA01A 0.0054
2 FA02A 0.0033
3 FA03A 0.0179
4 FA04A 0.0046
5 FA05A 0.0079
6 FA06A 0.0034
7 FA07A 0.0032
8 FA08A 0.0048
9 FA09A 0.0093
10 MA01A 0.0041
11 MA02A 0.0054
12 MA03A 0.0143
13 MA04A 0.0153
14 MA05A 0.0084
15 MA06A 0.0088
16 MA07A 0.0193
17 MA08A 0.0392
18 MA09A 0.0144
Fig. 1 Mass of RNA obtained in micrograms from 5 mL plasma (grey bars) for each donor specimen against the number of clean sequencing reads 
obtained in millions (Q ≥ 30) (red crosses)
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to be highly expressed by erythrocytes, whilst miRNAs 
181a-3p, 151a-3p and let-7f-5p were highly expressed 
by various blood cell types [11, 15]. To ensure our highly 
expressed miRNAs were naturally present at such levels, 
as opposed to the result of haemolysis, we determined 
the expression variation in both blood cell and non-blood 
cell associated miRNAs with the expectation that these 
should be equivalent in the absence of haemolysis. Vari-
ation in our blood cell associated miRNAs was in fact less 
than that of the non-blood cell associated miRNAs (Coef-
ficient of variation = 95.8 vs 116.3 %, N = 18), support-
ing our findings. Leveraging over 300 publically available 
next generation sequencing datasets (including 66, 13 
and 37 in human blood, serum and plasma respectively), 
we were able to determine the tissue expression profile 
of each highly expressed miRNA. Whilst each miRNA 
exhibited a different tissue based expression pattern, 
nine of the ten (miRNA-151-3p was the exception) highly 
expressed miRNAs identified herein had median expres-
sion levels in either blood, serum or plasma in excess of 
the median expression for all tissues, suggesting that the 
blood is a significant source of these. Furthermore, in 
considering only those miRNA-seq datasets generated 
from human plasma, nine of the ten (miR-10b-5p was 
the exception) top expressed miRNAs identified in this 
study appeared within the upper quartile of expression, 
confirming that our results mirror those of other studies 
conducted using similar methods in the same biological 
sample type. Comprehensive tissue expression data for 
the most highly expressed miRNAs identified in human 
plasma is included within Fig. 4.
Our realisation that a number of the most highly 
expressed miRNAs were of blood cell origin led us to 
consider the potential implications that this may have for 
biomarker development (for a comprehensive review of 
the challenges associated with miRNA biomarker devel-
opment, please refer to [16]. The routine clinical sampling 
of blood involves venapuncture, delivery to a suitable 
storage vessel with or without anticoagulant and delivery 
to the analytical laboratory. The preparation of plasma 
or serum involves a further step during which blood 
cells are removed by centrifugation to leave a “cell free” 
Fig. 2 a Schematic showing the bioinformatic approach taken for miRNA sequencing and mapping. b Number of clean sequencing reads 
obtained in millions (Q ≥ 30) (sum of blue, red and green bar elements), total number of reads of miRNA size (sum of red and green elements) and 
the total number of reads mapped to miRBase (green element) for each study participant. c Total number of miRNAs mapped for each study par-
ticipant sorted according to gender (blue—males, pink—females) (n = 9, N = 18). Note, only those miRNAs detected by at least ten independent 
sequencing reads, and that were present in at least three study participants are included
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supernatant. At each point, there is potential to influ-
ence the number of blood cell associated miRNAs pre-
sent in the remaining sample either through haemolysis 
following venapuncture or during transportation, or via 
variation in the time and or intensity of centrifugation. In 
support of this, Pritchard and colleagues have previously 
demonstrated significant increases in erythrocyte-associ-
ated miRNAs (miRs-451, 16, 92a, 486) in haemolysis, and 
explained miR-150 and 223 expression as a function of 
lymphocyte and neutrophil count respectively [15]. Thus, 
small variations in blood sample preparation may lead to 
individual samples being enriched or depleted in certain 
blood cell types and thus have significant impacts upon 
the expression of specific miRNAs. Of concern is the 
fact that all of the blood cell associated miRNAs identi-
fied herein have been identified in biomarker screens and 
or proposed as novel biomarkers for various conditions 
(miR-486-5p—gastric adenocarcinoma, miR-92a-3p—
colorectal cancer, miR-181-5p—endometrial carcinoma, 
miR-151a-3p—paracetamol toxicity, let-7f-5p—Alzhei-
mer’s disease) and may thus be subject to the aforemen-
tioned issues.
In order to determine the normal range of circulat-
ing miRNA expression within our disease free popula-
tion, the mean and the standard error of the normalised 
expression values was calculated and the miRNAs ranked 
according to their apparent stability. The most stably 
expressed miRNAs included microRNAs 486-5p, 25-3p, 
10b-5p, 99b-5p, let-7f-5p, 10a-5p, 423-3p, 101-3p, 532-5p, 
and 103a-3p (Fig. 5). Although several of the most abun-
dantly expressed miRNAs were identified, these highly 
stable miRNAs represented several orders of expres-
sion magnitude including both highly abundant and very 
lowly expressed miRNAs. Wang et al. [18] have previously 
reported the stability of a restricted set of plasma and 
serum miRNAs and despite differences in experimental 
design and measurement techniques, various miRNAs 
were identified as highly stable in both studies (Table 4).
The sole inclusion criterion for this study was the 
requirement to be free from overt disease at the time of 
blood donation and thus our patient cohort was diverse 
in their gender, smoking status and BMI. It was there-
fore possible to determine the effects of these factors 
Table 3 Details of miRNAs detected in all plasma samples 
analysed (18 out of 18 individuals)
miRNA Normalised expression
hsa-miR-486-5p 56.91769
hsa-miR-25-3p 0.263462
hsa-miR-10b-5p 14.94519
hsa-miR-99b-5p 0.033431
hsa-let-7f-5p 0.858338
hsa-miR-10a-5p 1.412167
hsa-miR-423-3p 0.060593
hsa-miR-101-3p 0.046649
hsa-miR-103a-3p 0.037811
hsa-miR-191-5p 0.548739
hsa-miR-423-5p 2.303739
hsa-miR-182-5p 0.201054
hsa-miR-30a-5p 0.134701
hsa-let-7a-5p 0.515206
hsa-miR-21-5p 0.215671
hsa-miR-150-5p 0.235879
hsa-miR-22-3p 1.557981
hsa-miR-28-3p 0.305134
hsa-let-7i-5p 0.186836
hsa-miR-30e-5p 0.036269
hsa-miR-16-5p 0.07779
hsa-miR-92a-3p 2.20284
hsa-miR-126-5p 0.271752
hsa-miR-30d-5p 0.105128
hsa-miR-451a 0.041124
hsa-miR-92b-3p 0.129143
hsa-miR-26a-5p 0.211624
hsa-miR-140-3p 0.034428
hsa-miR-375 0.295206
hsa-miR-27b-3p 0.273707
hsa-miR-143-3p 0.423736
hsa-miR-328 0.021033
hsa-miR-146b-5p 0.094907
hsa-miR-125a-5p 0.062047
hsa-miR-1246 0.050083
hsa-miR-181a-5p 1.238587
hsa-miR-222-3p 0.026529
hsa-miR-192-5p 0.196152
hsa-miR-148a-3p 0.102086
hsa-miR-146a-5p 0.399876
hsa-let-7b-5p 0.051522
hsa-miR-127-3p 0.094643
hsa-miR-151a-3p 1.164533
hsa-miR-409-3p 0.141178
hsa-miR-584-5p 0.058182
hsa-miR-186-5p 0.095506
hsa-miR-378a-3p 0.559047
hsa-miR-320a 2.876669
Table 3 continued
miRNA Normalised expression
hsa-miR-769-5p 0.113601
hsa-miR-181b-5p 0.09218
hsa-miR-184 0.083304
hsa-miR-4448 0.04067
hsa-miR-320d 0.035856
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on circulating miRNA expression. Perhaps unsurpris-
ingly, the gender of the study participant had a significant 
effect on their circulating miRNA profile. Seventy-five 
miRNAs were differentially regulated between the two 
genders (Fig. 6a) however rather surprisingly 74 of these 
were up-regulated in females (in the absence of any sig-
nificant differences in RNA mass obtained, number 
of clean sequencing reads or indeed the percentage of 
reads mapped to miRNAs—Fig.  6b, c). MicroRNA 486-
5p, present in erythrocytes, was the only miRNA to be 
expressed at a higher level in males than in females, and 
we consider that this is likely due to the higher initial 
erythrocyte count that males present with. In considering 
why all of the deregulated miRNAs were elevated in the 
female sex, we determined the genomic location at which 
they were encoded with a hypothesis that there would 
be an over representation of miRNAs encoded by the X 
chromosome. In fact of the 75 miRNAs deregulated, only 
three were encoded at a locus on the X chromosome 
confirming that X copy number is unlikely responsible 
for this phenomenon. A review of the available literature 
reveals that few studies have previously investigated gen-
der-specific miRNA expression, and there is an absence 
of those that have specifically considered gender-specific 
expression in healthy human subjects. In order to validate 
our findings, we therefore returned to the 37 publically 
available plasma miRNA-seq datasets, 27 of which had 
gender information. Considering the 74 miRNAs differ-
entially expressed between male and female subjects in 
our study, we confirmed that 53 of these were also more 
highly expressed in the female sex of the publically avail-
able datasets.
We next considered the impact of smoking status on 
circulating miRNA expression. Of the 18 participants, 8 
(45  %) were self-reported smokers (an equal number of 
males and females). Smoking was associated with the 
down-regulation of 27 plasma miRNAs (Fig. 7), including 
several previously identified as performing tumour sup-
pressor-like functions; let-7i-5p [2], miR-148a-5p [22], 
miR-218-5p [17], miR-29-3p [20], miR-133a [4], miR-
296-5p [10] and miR-370 [21]. We consider this finding 
particularly interesting; however, these results should 
be confirmed by analysis of a larger cohort of smokers 
incorporating robust statistical techniques to control for 
false discovery. Various publications have investigated 
the impact of smoking on miRNA expression in the lungs 
[8] and lung cells [5] and have reported an apparent 
global down-regulation of miRNA regulation, potentially 
mediated via disruption of the Erk/dicer/trbp pathway 
[14]. Here, we show the same phenomenon in the plasma 
Fig. 3 Fraction of the total sequencing reads mapped occupied by each of the ten most highly expressed miRNAs (based upon the mean of 18 
samples) are presented (grey bars) ± S.E.M. The mean expression in human plasma, serum and whole blood derived from 116 publically avail-
able datasets is included on the right hand axis for comparison (reads per million—RPM ± S.E.M, in Log2 form). Note for clarity, errors bars are only 
included for the plasma datasets
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however, there is little agreement at present between 
the dysregulated miRNAs identified in each individual 
study—perhaps reflecting a difference in the smoking 
cohort, experimental setup or suggesting that there are 
tissue specific effects.
Finally, we considered the effects of obesity on the cir-
culating miRNA profile of our study participants. Of the 
18 donors, 8 had a BMI of greater or equal to 30 and were 
considered obese (2 males and 6 females). Sixteen miR-
NAs were dysregulated in obese individuals, and were 
more highly expressed compared to normal weight con-
trol subjects in all cases (Fig. 8a). Given that our donors 
had a range of BMI values, we sought to determine 
whether any of the obesity-associated miRNAs correlated 
with BMI. The expression of both miR-129-5p and miR-
30e-3p were found to correlate with obesity (R  =  0.67 
and 0.64 respectively) (Fig. 8b, c). In both cases, the rela-
tionship was stronger amongst female participants how-
ever it is highly likely that this effect is down to a higher 
number of females than males being obese.
Conclusions
The potential of miRNAs to serve as novel biomark-
ers is under intense investigation. To date, numerous 
studies have attempted to correlate miRNA expression 
with a range of endpoints. Despite the number of stud-
ies reporting such miRNA biomarkers, there is still a 
relative paucity of baseline data reporting the miRNA 
species expressed in a given biological fluid, what is 
considered normal in terms of their patterns of expres-
sion, and further, how this expression is altered by 
gender, obesity and smoking status. In this study we 
utilised state of the art sequencing technology to pro-
vide data to support the above key questions. In excess 
of 500 miRNAs were detected in our study population 
with expression across several orders of magnitude. 
However, only 53 of those miRNAs were detected in all 
participants with some miRNAs being detected in just 
a single individual. In considering relative expression 
between miRNAs, the top 10 most highly expressed 
candidates accounted for 90  % of the total reads that 
mapped to all miRNAs suggesting that despite the 
range of miRNAs present, the total miRNA load of the 
plasma was predominated by just 10 different species. 
Furthermore, many of the most abundant miRNAs 
have been shown to be highly expressed in cells of the 
blood and thus, perhaps with the exception of haema-
tological biomarkers, their use as biomarkers should be 
approached with caution. Ranges of expression were 
determined for all miRNA detected (> 500) and a set of 
Fig. 4 Tissue based expression data for the ten most highly expressed miRNAs detected in human plasma. Data are reads per million (RPM) in Log 
2 form obtained from miRMine online (Guan Laboratory, University of Michigan). Box and whisker plots identify the minimum and maximum, upper 
and lower quartile and median values
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highly stable miRNAs identified. Finally, the effects of 
gender, smoking status and BMI on miRNA expression 
were determined. These data provide researchers with 
the ability to (1) determine the presence or absence of 
individual miRNAs within the plasma of a disease-free 
population, (2) consider the penetrance of each indi-
vidual miRNA, (3) gain insight into the relative expres-
sion levels and “normal range” of individual miRNAs, 
ensuring that only suitabily highly expressed and stable 
candidates are taken forward, and (4) to have an indi-
cation of whether individual miRNAs are regulated by 
gender, smoking or obesity. Perhaps most striking and 
of most relevance here is the finding that of the large 
pool of miRNA detected in disease-free plasma, only a 
very small proportion of this may house suitable bio-
marker candidates (considering that, with the excep-
tion of the 10 most highly expressed miRNAs, only 10 % 
of the total miRNA pool is left and once miRNAs with 
low penetrance, those associated with cells of the blood, 
and those with high levels of inter-individual varia-
tion are discounted). Thus, the information contained 
within will assist researchers in designing more targeted 
miRNA biomarker studies.
Methods
Ethical approval and consent to participate
Sample collection was undertaken by Sera Lab ltd. who 
obtained ethical approval by an Institutional Review 
Board (Schulman Associates IRB #201209850). Written 
informed consent to participate was obtained from each 
study participant prior to sample collection.
Consent for publication
The supplying company (Sera Lab ltd) obtained written 
consent to produce reports or articles about the study 
from each participant, subject to their names being omit-
ted from any such publications.
Samples, RNA isolation and sequencing
This study utilised human control material purchased 
from SeraLab ltd. All data were analysed anonymously; 
donor details are included in Table 1. Whole blood was 
drawn into EDTA containing tubes and stored on ice 
prior to centrifugation at 1000×g to obtain the plasma 
component. Plasma samples were frozen at −20  °C 
immediately after production. RNA was extracted 
from 5  mL of each plasma sample using the QiaAmp 
Fig. 5 Mean normalized expression +/− standard error of the mean (S.E.M) for the ten most stably expressed miRNAs (N = 18)
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Circulating Nucleic Acid extraction kit in accordance 
with the manufacturer’s standard instructions. The 
quantity and quality of all RNA extracts was determined 
using the QuBit fluorimeter (Invitrogen) and Agilent 
BioAnalyzer (with Small RNA chip) respectively. Small 
RNA sequencing libraries were preparing using the 
TruSeq Small RNA kit according to the manufacturer’s 
standard directions. Sequencing was conducted on the 
Illumina HiSeq 2000 platform with the aim of obtaining 
>5,000,000 reads per sample.
Table 4 Comparison of  the most stable miRNAs (90th percentile for  stability) identified in  this study with  plasma 
and serum data from [18]
Italicised miRNAs—identified as stable in plasma in both studies. Italicised and underlined miRNAs—identified as being stable in plasma herein, and in serum by 
Wang et al
Wang et al. (top 10 % stable  
plasma miRNAs)
Wang et al. (top 10 % stable  
serum miRNAs)
Tonge et al. (top 10 % stable 
plasma miRNAs)
hsa-miR-106b hsa-miR-106b hsa-let-7a-5p
hsa-miR-16 hsa-miR-126 hsa-let-7f-5p
hsa-miR-185 hsa-miR-140-3p hsa-let-7i-5p
hsa-miR-18a hsa-miR-185 hsa-miR-101-3p
hsa-miR-19b hsa-miR-191 hsa-miR-103a-3p
hsa-miR-222 hsa-miR-1974 hsa-miR-106b-3p
hsa-miR-320a hsa-miR-1979 hsa-miR-10a-5p
hsa-miR-320b hsa-miR-19b hsa-miR-10b-5p
hsa-miR-324-3p hsa-miR-320a hsa-miR-126-3p
hsa-miR-345 hsa-miR-320b hsa-miR-126-5p
hsa-miR-346 hsa-miR-324-3p hsa-miR-130a-3p
hsa-miR-484 hsa-miR-345 hsa-miR-130b-3p
hsa-miR-486-5p hsa-miR-346 hsa-miR-148b-3p
hsa-miR-720 hsa-miR-451 hsa-miR-150-5p
hsa-miR-92a hsa-miR-720 hsa-miR-151a-5p
hsa-miR-92a hsa-miR-16-5p
hsa-miR-934 hsa-miR-181a-3p
hsa-miR-182-5p
hsa-miR-191-5p
hsa-miR-21-5p
hsa-miR-22-3p
hsa-miR-221-3p
hsa-miR-25-3p
hsa-miR-26b-5p
hsa-miR-28-3p
hsa-miR-30a-3p
hsa-miR-30a-5p
hsa-miR-30d-5p
hsa-miR-30e-5p
hsa-miR-340-5p
hsa-miR-342-3p
hsa-miR-423-3p
hsa-miR-423-5p
hsa-miR-451a
hsa-miR-484
hsa-miR-486-5p
hsa-miR-532-5p
hsa-miR-92a-3p
hsa-miR-92b-3p
hsa-miR-99b-5p
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Fig. 6 a Heat map diagram showing the effects of gender (pink squares—female, blue squares—male) on plasma miRNA expression. Data are nor-
malised expression values determined by next generation sequencing, ordered by descending fold change where P < 0.05. The colour bar indicates 
the range of normalised expression values from −2 (green) to +2 (red). b–d RNA mass, number of clean sequencing reads and the proportion of 
mapped reads (%) separated by gender
Fig. 7 Heat map diagram showing the effects of smoking (black squares) on plasma miRNA expression. Data are normalised expression values 
determined by next generation sequencing, ordered by descending fold change where P < 0.05. The colour bar indicates the range of normalised 
expression values from −2 (green) to +2 (red)
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Bioinformatic analysis
All sequencing data underwent stringent quality con-
trol measures prior to analysis. Briefly, reads were qual-
ity clipped to only retain reads with a median quality of 
≥Q30, sequencing adapters removed, and read length 
distributions assessed to ensure these met the expecta-
tions of a miRNA sequencing run. An extract and count 
routine was utilised to condense the millions of sequenc-
ing reads into sequence tab count format to increase 
computational efficiency. Reads shorter than 15 nucleo-
tides and longer than 35 nucleotides were filtered given 
that these were unlikely to map to miRNAs. Following 
parsing to remove superfluous data columns, the result-
ing tally tables comprising the miRNA sequence and 
count were processed by miRanalyzer V0.2 [6]. Reads 
were mapped to the human genome (hg18) and to miR-
Base version 20.0 permitting one mismatch between 
the sequencing reads and each index. Reads mapping 
to known miRNAs were counted and a relative expres-
sion value determined by dividing the number of reads 
mapping to each particular miRNA by the total number 
of reads mapped to all miRNAs. MicroRNAs evidenced 
by less than 10 sequencing reads or present in less than 
three study individuals were excluded prior to further 
analysis. Differential expression analysis and P value esti-
mation were performed using QluCore Omics Explorer. 
The significance of differences between the various fac-
tors (BMI, smoking status and gender) was determined 
using a two-tailed t-test. In each case, contributions 
from other factors were eliminated using QluCore Omics 
explorer.
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